The American company Enveda announced the successful completion of the first phase of clinical trials for its experimental drug. This medication was developed using machine learning algorithms and is capable of inducing metabolic changes in the body similar to those that occur during intense physical activity.
The main action of the drug is appetite reduction and decrease in fat mass. During pilot studies involving healthy volunteers, it was confirmed that the drug is safe, well tolerated by the body, and possesses optimal pharmacokinetics. Furthermore, a reduction in leptin hormone concentration was noted after taking this substance.